
    
      "The study will have four groups: Group HRV + OPV, Group HRV alone, Group Placebo + OPV and
      Group Placebo alone. Two-dose immunisation will be administered in healthy infants at
      approximately 12 and 16 weeks of age. Immunogenicity, reactogenicity and safety relative to
      the placebo will also be evaluated. Treatment allocation: randomized (2:2:1:1). Routine EPI
      vaccines should be administered during the study following the EPI recommendation in
      Bangladesh."
    
  